Randomized phase II trial evaluating treatment with EGFR-TKI associated with anti-estrogen in women with non-squamous advanced stage NSCLC: IFCT-1003 LADIE trial.
Fiche publication
Date publication
mars 2020
Journal
Clinical cancer research : an official journal of the American Association for Cancer Research
Auteurs
Membres identifiés du Cancéropôle Est :
Dr DEBIEUVRE Didier, Dr MENNECIER Bertrand, Pr WESTEEL Virginie
Tous les auteurs :
Mazieres J, Barlesi F, Rouquette I, Molinier O, Besse B, Monnet I, Audigier-Valette C, Toffart AC, Renault PA, Fraboulet S, Hiret S, Mennecier B, Debieuvre D, Westeel V, Masson P, Madroszyk-Flandin A, Pichon E, Cortot AB, Amour E, Morin F, Zalcman G, Moro-Sibilot D, Souquet PJ
Lien Pubmed
Résumé
The incidence of lung cancer has dramatically increased in women. Preclinical data have suggested that combining EGFR-TKI with an anti-estrogen may overcome resistance to EGFR-TKI.
Référence
Clin. Cancer Res.. 2020 Mar 6;: